After ICH, starting long-term therapeutic oral anticoagulation in patients with AF reduces MACE at 1 to 3 y

Area of Science:

• Neurology
• Hematology
• Clinical Trials

Background:

• Intracerebral hemorrhage (ICH) is a severe type of stroke.
• The role of antithrombotic treatment following ICH remains controversial.
• Existing guidelines offer limited recommendations due to safety concerns.

Purpose of the Study:

• To systematically review the evidence on antithrombotic treatment after stroke due to intracerebral hemorrhage.
• To evaluate the efficacy and safety of antithrombotic agents in this patient population.

Main Methods:

• A comprehensive search of multiple databases was conducted.
• Included randomized controlled trials and observational studies comparing antithrombotic treatment with placebo or no treatment.
• Risk of bias and quality of evidence were assessed.

Main Results:

• Antithrombotic treatment was associated with an increased risk of hemorrhagic progression and mortality.
• No significant reduction in the risk of ischemic events was observed.
• Heterogeneity in study designs and patient populations limited definitive conclusions.

Conclusions:

• Current evidence does not support the routine use of antithrombotic treatment after intracerebral hemorrhage.
• Further high-quality research is necessary to identify potential benefits in selected patient groups.
• Risk stratification and individualized treatment approaches are crucial.